AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application
10 mai 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease...
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests
27 avr. 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye...
AXIM Biotechnologies CEO Issues Letter to Shareholders
19 avr. 2022 08h30 HE
|
AXIM BIOTECHNOLOGIES, INC
Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic systemPlans to address largely underserved DED diagnosis market with patent pending tear...
AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease
08 mars 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye...
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test
07 mars 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye...
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
15 févr. 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab...
CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies
21 déc. 2021 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19...
AXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests
18 nov. 2021 11h15 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological,...
AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19
16 nov. 2021 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19...
AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity
09 nov. 2021 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19...